Antibodies against SARS-CoV-2 mutants and uses thereof

A technology of antibodies and variants, applied in the direction of antibodies, applications, antiviral agents, etc., can solve problems such as the impact of vaccine effectiveness

Active Publication Date: 2021-10-19
PEKING UNIV
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the emergence of mutant strains with multiple mutations, such as B.1.1.7, B.1

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies against SARS-CoV-2 mutants and uses thereof
  • Antibodies against SARS-CoV-2 mutants and uses thereof
  • Antibodies against SARS-CoV-2 mutants and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0152] Example 1: Preparation of Antibodies BD812 and BD836

[0153] 1.1 Obtaining antibody sequences

[0154] 1) Isolation of B cells

[0155] The blood (provided by Beijing You'an Hospital) was collected from persons infected with SARS-CoV-2 virus and cured for more than half a year, and peripheral blood mononuclear cells were extracted. Utilize STEMCELL EasySep TM Human BCell Isolation Kit (STEMCELL, 17954) isolates B cells from peripheral blood mononuclear cells.

[0156] 2) Enrichment and sequencing of antigen-specific B cells

[0157] Combining antigenic proteins (RBD, S1, S2) with DNA oligonucleotides and fluorescent streptavidin into a complex: combine RBD (Sino Biological 40592-V27H-B) with TotalSeq TM -C0951 PE Streptavidin (Biolegend 405261) was assembled into a complex according to the manufacturer's instructions. Similarly, S1 (Sino Biological40591-V27H-B) and TotalSeq TM -C0952 PE Streptavidin (Biolegend 405263), S2 (SinoBiological 40590-V08B-B) TotalSeq TM -...

Embodiment 2

[0163] Example 2: Identification of Antigen Binding Ability of Antibodies BD812 and BD836

[0164] Using recombinantly expressed RBD (Sinobiologicals, Cat: 40592-V08B, which contains RBD fragment sequence YP_009724390.1 and His tag) as the coating antigen, horseradish peroxidase (HRP)-labeled Goat Anti-Human IgG (H +L) (Jackson, 109-036-088) was used as the secondary antibody, and the reaction specificity of the purified antigen was detected by ELISA experiment. Briefly, a 96-well plate was coated with the recombinantly expressed S protein RBD (the amino acid sequence of which is SEQ ID NO: 41), and then the 96-well plate was blocked with a blocking solution. Then, monoclonal antibodies to be tested (irrelevant control antibodies, BD812, BD836) were added and incubated. After washing with ELISA washing solution, horseradish peroxidase-labeled Goat Anti-Human IgG (H+L) was added as a secondary antibody (diluted at 1:5000), and the incubation was continued. Wash the ELISA plat...

Embodiment 3

[0170] Example 3: Evaluation of Antibody BD812 and BD836 Neutralizing Pseudovirus Ability

[0171] The SARS-CoV-2 pseudovirus (mutant strain pseudovirus) used in this experiment was provided by the China Institute for Food and Drug Control. This pseudovirus can simulate the similar cell infection characteristics of the real virus, and carries a fluorescein reporter gene for detection. For the experimental steps, please refer to: Nie, J., Li, Q., Wu, J. et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc 15, 3699–3715(2020). https: https: / / doi.org / 10.1038 / s41596-020-0394-5. Specific steps are as follows:

[0172] 1) The arrangement of the samples in the 96-well plate is as follows: B2-G2 is the cell control well (CC), containing Huh-7 cells without antibody samples and pseudoviruses; B3-G3 is the virus control well (VC), containing Huh-7 cells and pseudoviruses, without antibody samples; wells B4-G11 are experimental wells,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Concentrationaaaaaaaaaa
Login to view more

Abstract

The invention relates to the fields of immunology and molecular virology, in particular to the fields of diagnosis, prevention and treatment of SARS-Cov-2. In particular, the present invention provides monoclonal antibodies that can recognize SARS-Cov-2 mutants, as well as compositions (e.g., diagnostic agents and therapeutic agents) comprising the antibodies. In addition, the invention also relates to application of the antibody. The antibody of the invention can be used for diagnosis, prevention and/or treatment of SARS-Cov-2 infection and/or diseases caused by the infection (e.g., COVID-19).

Description

technical field [0001] The present invention relates to the field of immunology and molecular virology, especially the field of diagnosis, prevention and treatment of SARS-Cov-2. Specifically, the present invention provides monoclonal antibodies that can recognize mutant strains of SARS-Cov-2, and compositions (eg, diagnostic and therapeutic agents) comprising the antibodies. Furthermore, the present invention also relates to the use of said antibody. Antibodies of the invention can be used to diagnose, prevent and / or treat SARS-Cov-2 infection and / or diseases caused by said infection (eg, COVID-19). Background technique [0002] Global vaccination may be the inevitable means to end the SARS-CoV-2 pandemic. Current vaccines protect primarily by eliciting neutralizing antibody responses to the spike protein derived from earlier isolates. However, the emergence of mutant strains with multiple mutations, such as B.1.1.7, B.1.351, B.1.617.1, and B.1.617.2, etc., may affect th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K16/10C12N15/13C12P21/02A61K39/395A61P31/14G01N33/569G01N33/577
CPCC07K16/10A61P31/14G01N33/56983G01N33/577C07K2317/56C07K2317/565C07K2317/92A61K2039/505G01N2333/165G01N2469/10
Inventor 曹云龙谢晓亮
Owner PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap